QTTB: Q32 Bio Corp Price to Sales
Q32 Bio Inc. develops innovative immunotherapies, leveraging strategic alliances with pharmaceutical behemoths to fund research. The price-to-sales ratio reflects the market valuation of the business relative to its revenue, with the 4.90 level serving as a critical benchmark. Experienced management maintains strict financial discipline, while high development costs and patents create insurmountable barriers to entry for competitors.
Analytical breakdowns for Q32 Bio Inc. (QTTB)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
- earnings and market multiples details:
QTTB - Net Profit|Company Profit Forecast Q32 Bio Inc.|QTTB - Price to Earnings Ratio|Price to Future Earnings Ratio q32bio.com|QTTB - PEG Multiple|Enterprise Value to EBITDA Ratio Q32 Bio Corp|QTTB - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Q32 Bio|QTTB - Earnings per share for the last twelve months|Net earnings per share growth for the trailing year q32bio.com|QTTB - Net earnings per share growth this year|Projected earnings per share increase next year Q32 Bio Inc.
- sales revenue and business income indicators:
General company analysis:QTTB, Q32 Bio Inc
The development of Q32 Bio Inc. (QTTB) depends directly on the results of clinical trials for autoimmune pathology therapies and available funding. The P/S ratio relates market capitalization to annual revenue, demonstrating how much investors are willing to pay per unit of sales. Low values minimize the risk of overpayment, while sharp spikes signal inflated market expectations. By analyzing the price-to-sales valuation, one can determine an entry point with an optimal balance of risk and return.
Competitors of Q32 Bio Inc.
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price-to-Revenue Multiple Protagonist Corp (PTGX)|IMVT (Immunovant, Inc.) - Market Cap to Revenue|KNSA (kiniksa.com) - Price-to-Revenue Ratio|Market Cap to Revenue GRFS|ADPT: Market Capitalization-to-Revenue Ratio|P/S Multiple CLDX|Price-to-Revenue Ratio AUPH (Aurinia Corp)|P/S Multiple BCRX (BioCryst)|Price-to-Revenue Coefficient veratx.com (VERA)|DNTH - Price-to-Revenue Ratio|Price to Sales Pharvaris NV|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline - Market Capitalization-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|pharming.com (PHAR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|Upstream Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|IMNM - Market Cap to Revenue|GOSS: Market Cap to Revenue|Price-to-Revenue Coefficient kalvista.com KALV|Septerna (SEPN) - Price-to-Revenue Ratio|Price-to-Revenue Multiple Pieris Pharma PVLA|Market Cap to Revenue SVRA|RIGL (Rigel Corp) - Market Cap to Sales Volume|Market Cap to Revenue ANAB (AnaptysBio, Inc.)|Market Cap to Sales Volume ATXS|P/S Multiple ENGN (enGene)|RAPT Therapeutics Inc. - Price-to-Revenue Ratio|JBIO - Price-to-Revenue Ratio|Price-to-Sales Ratio ACRS|KYTX: P/S Multiple|tizianalifesciences.com - Market Capitalization-to-Revenue Ratio|CABA (Cabaletta Bio) - P/S Multiple|P/S Multiple Ventyx Biosciences Inc.|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|AVTX (Avalo Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN - Market Cap to Revenue|Climb Bio - P/S Multiple|ZURA - P/S Multiple|ATYR (aTyr) - Market Cap to Revenue|Adagene Inc. - Market Capitalization-to-Revenue Ratio|IMA (ImageneBio) - P/S Multiple|Shattuck Therapeutics (STTK) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Equillium, Inc. (EQ)|Market Cap to Revenue connectbiopharm.com CNTB|Price-to-Revenue Ratio Immunic IMUX|ATRA - Market Cap to Revenue|IFRX: Market Cap to Revenue|XFOR - P/S Multiple|adicetbio.com (ACET) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CELU|INMB (INmune Bio Corp) - P/S Multiple|Price to Sales Barinthus Biotherapeutics Corp BRNS|Price-to-Revenue Ratio Kezar Life Sciences (KZR)|sabbiotherapeutics.com (SABS) - Price-to-Revenue Multiple|Akari Therapeutics Plc - Market Cap to Revenue|Enlivex Therapeutics Ltd - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio EDSA (Edesa Biotech Corp)|IBIO: P/S Multiple|CARM (Carisma Therapeutics Inc.) - Price-to-Revenue Ratio|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Bolt Bio (BOLT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|APVO - Price to Sales|AIM ImmunoTech Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio - P/S Multiple|Price-to-Revenue Coefficient XORTX Therapeutics Inc XRTX|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio REVB|INDP (Indaptus Therapeutics) - P/S Multiple|Market Cap to Revenue scinai.com (SCNI)|Market Cap to Revenue CALI (CalciMedica, Inc.)|Price-to-Revenue Coefficient affimed.com|Price-to-Revenue Ratio Allakos ALLK|Price-to-Revenue Multiple HOOKIPA Pharma, Inc.|IGMS: Market Cap to Revenue|iteostherapeutics.com - Market Cap to Sales Volume|OCEA (Ocean Biomedical) - Market Cap to Revenue|TCBP: Market Cap to Sales Volume|THRD (Third Harmonic Bio, Inc) - P/S Multiple
